NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637105. A total of 42 filers reported holding NABRIVA THERAPEUTICS PLC in Q2 2018. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $20,000 | -97.0% | 38,143 | -88.6% | 0.00% | -100.0% |
Q3 2019 | $666,000 | -3.8% | 333,364 | +17.1% | 0.00% | 0.0% |
Q2 2019 | $692,000 | +220.4% | 284,576 | +221.9% | 0.00% | – |
Q1 2019 | $216,000 | +22.7% | 88,411 | -26.7% | 0.00% | – |
Q4 2018 | $176,000 | -47.1% | 120,573 | -2.2% | 0.00% | – |
Q3 2018 | $333,000 | -92.0% | 123,284 | -85.0% | 0.00% | -100.0% |
Q1 2018 | $4,140,000 | -20.2% | 823,001 | -5.1% | 0.01% | -14.3% |
Q4 2017 | $5,188,000 | +579.1% | 867,613 | +1089.8% | 0.01% | +600.0% |
Q2 2017 | $764,000 | – | 72,922 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 191,028 | $462,000 | 0.08% |
Sterling Investment Advisors, Ltd. | 5,000 | $12,000 | 0.00% |
IFP Advisors, Inc | 0 | $0 | 0.00% |